Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Thiogenesis Therapeutics Corp ( (TSE:TTI) ) is now available.
Thiogenesis Therapeutics Corp. has entered into a consulting and investor relations agreement with Bull Markets Media GmbH to expand its shareholder base and network in Europe. The agreement involves a consultancy fee and stock options, with the possibility of annual renewal for two additional years, subject to TSX Venture Exchange approval. This strategic move is expected to enhance Thiogenesis’s market presence in Europe, potentially impacting its operations and stakeholder engagement positively.
More about Thiogenesis Therapeutics Corp
Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing sulfur-containing prodrugs that become active only upon metabolism. These prodrugs aim to treat serious pediatric diseases with unmet medical needs, leveraging streamlined regulatory pathways to enhance drug bioavailability and reduce side effects. Target indications include MELAS, Leigh syndrome, Rett syndrome, and pediatric MASH.
YTD Price Performance: 10.0%
Average Trading Volume: 20,167
Technical Sentiment Consensus Rating: Sell
Current Market Cap: C$29.08M
Learn more about TTI stock on TipRanks’ Stock Analysis page.